Printer Friendly

IMMULOGIC AND MERCK EXTEND COLLABORATION TO DEVELOP NEW TREATMENTS FOR AUTOIMMUNE DISEASES

 IMMULOGIC AND MERCK EXTEND COLLABORATION TO DEVELOP
 NEW TREATMENTS FOR AUTOIMMUNE DISEASES
 CAMBRIDGE, Mass., April 6 /PRNewswire/ -- ImmuLogic Pharmaceutical Corporation (NASDAQ: IMUL) today announced that Merck & Co., Inc. has elected to extend its ongoing collaborative research program with ImmuLogic until September 1993. The program is focused on the development of new treatments for autoimmune diseases such as rheumatoid arthritis and type I diabetes.
 The Merck action extends a collaboration that began in 1989. "We are pleased that Merck has made this decision to continue our collaboration. We believe it reflects our progress to date and the expectation of a successful drug program," said Richard E. Bagley, president and CEO of ImmuLogic. The initial agreement called for Merck to fund the ImmuLogic research effort until September 1992 with options for two one-year extensions. The Merck option for a second one-year extension, through September 1994, is still outstanding.
 The research collaboration is specifically aimed at identifying and designing compounds called HLA blockers. HLA molecules, which play a key role in the initial stages of the immune response, are believed to be appropriate targets for the treatment of autoimmune diseases. Under the agreement, ImmuLogic will receive royalties on the sales of products resulting from the collaboration.
 ImmuLogic is developing products to treat allergies and autoimmune diseases. The company's technical approach is based upon proprietary discoveries and an advanced understanding of the molecular events controlling the human immune system. ImmuLogic is developing the ALLERVAX(tm) family of allergy therapeutics under a joint commercialization agreement with Marion Merrell Dow Inc., and the company is collaborating with Merck & Co., Inc. to develop treatments for type I diabetes and rheumatoid arthritis.
 -0- 4/6/92 R
 /CONTACT: Janet Bush, vice president, finance and administration, ImmuLogic, 617-494-0060/
 (IMUL) CO: ImmuLogic Pharmaceutical Corporation; Merck & Co. ST: Massachusetts IN: MTC SU:


TM -- NE004R -- 5272 04/06/92 10:13 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 6, 1992
Words:310
Previous Article:NEW NBI LEGACY(R) VERSION SUPPORTS MICROSOFT WINDOWS 3.1-CUSTOMIZABLE ICON BAR, OLE AND DRAG AND DROP FUNCTIONALITY LEAD AS NEW FEATURES
Next Article:GREEN MACHINE NETWORK REPORTS RECORD GROWTH FOR 1991


Related Articles
IMMULOGIC APPOINTS SENIOR DIRECTOR, REGULATORY AFFAIRS
IMMULOGIC ANNOUNCES PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK AT $22.75 PER SHARE
IMMULOGIC REPORTS FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
IMMULOGIC STUDIES OPEN WAY TO NEW TREATMENTS FOR ALLERGIC DISEASES
IMMULOGIC AND MERCK EXTEND COLLABORATION TO DEVELOP NEW TREATMENTS FOR AUTOIMMUNE DISEASES
IMMULOGIC ANNOUNCES START OF HUMAN CLINICAL TRIAL PROGRAM FOR CATVAX CAT ALLERGY THERAPY
IMMULOGIC REPORTS FIRST QUARTER RESULTS
IMMULOGIC REPORTS SECOND QUARTER RESULTS
IMMULOGIC REPORTS SECOND QUARTER RESULTS
ImmuLogic Files Investigational New Drug Application with the FDA for Multiple Sclerosis Therapeutic

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters